Rockefeller University scientists have analysed soils from beaches, forests, and deserts on five continents and discovered the best places in the world to mine untapped antibiotic and anticancer drugs.
The findings, published in the open-access journal eLife, provide new insights into the natural world as well as a road map for future drug discovery. The scientists now want to collect more samples from unique environments such as caves, hot springs, islands and city parks. They will continue with their citizen science effort, Drugs from Dirt, inviting the public to submit samples.
While there are more microbes in a teaspoon of soil than there are humans on earth, only a tiny fraction have been cultured. Of these, only a small number of the potentially clinically useful chemicals produced by bacteria have been studied.
For this study, one hundred and eighty five samples were taken from rainforests, temperate forests, deserts, and beaches on five continents (North America, South America, Africa, Asia and Australia) and the oceanic islands of Hawaii and Dominican Republic. The study of the “biosynthetic” content of these soils shows their potential for drug discovery.
“Uncultured bacteria from the environment could provide a dazzling array of new molecules, many of which could become new medicines,” says lead author and postdoctoral fellow Zachary Charlop-Powers from The Rockefeller University in New York.
“The unbelievable diversity we found is a first step towards our dream of building a world map of chemicals produced by microbes — similar to Google Earth’s and others’ maps of the world’s geography,” says Dr Sean Brady, head of the Laboratory of Genetically Encoded Small Molecules also at The Rockefeller University in New York.
The vast majority of antibiotics in clinical use today are derived from soil bacteria, but the yield of new drugs is low because the same cultivated bacteria, and the set of molecules they synthesise, are repeatedly rediscovered. However, for every cultured bacterial species, there are 100 uncultivated species in the environment.
Scientists have previously identified clusters of bacterial genes that are particularly good at producing therapeutics. This knowledge meant the scientists could focus on searching for certain types of gene clusters in samples rather than having to sequence and analyse the whole genomes of bacteria.
The team compared environmentally derived DNA to DNA from laboratory-grown bacteria chosen for their ability to make more than 400 natural product compounds. The analysis revealed soils particularly rich in important gene clusters.
The Latest on: Drug discovery
[google_news title=”” keyword=”Drug discovery” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Drug discovery
- Revolutionising drug discovery with the confluence of AI and geneticson March 4, 2024 at 8:41 pm
Somdip Dey is the cofounder and Chief Scientist of Nosh Technologies, an MIT Innovator Under 35 (Europe) in AI/Robotics and a Professor of Practice (AI/ML) at the Woxsen University. LESS... MORE In ...
- UG's Dr. Richard Amewu leads major project to accelerate malaria drug discoveryon March 4, 2024 at 9:19 am
Under the Grand Challenges Africa Drug Discovery Accelerator (GC ADDA) programme, Dr. Richard Amewu, a Senior Lecturer at the Department of Chemistry and Head of the Drug Innovations Group at the ...
- Global Drug Discovery Outsourcing Market Size is Estimated to Reach USD 6370 million by 2030, Growing at a CAGR of 7.6%: Straits Researchon March 4, 2024 at 4:36 am
North America's drug discovery outsourcing industry share leads with a 6.8% CAGR, driven by the U.S.'s dominant role in pharmaceutical sales and R&D investment. Europe follows with a 7.1% CAGR, ...
- Biochemists urged to expedite efforts towards drug discovery objectiveon March 3, 2024 at 3:15 pm
FAISALABAD: Experts at international symposium have urged the biochemists to expedite their efforts in term of ...
- Dr Krystyn Van Vliet Discusses Using 3D Platforms to Overcome MS Drug Discovery Barrierson March 2, 2024 at 6:00 am
Krystyn Van Vliet, PhD, vice president for research and innovation at Cornell University, discusses MS drug discovery barriers and overcoming them using 3D platforms.
- Eurofins Discovery Introduces Innovative DiscoveryAI SAFIRE: A New AI-Driven Platform for Drug Discovery Trained Using Proprietary Datasetson February 29, 2024 at 2:00 pm
Eurofins Discovery, an industry-leading provider of products and services for drug discovery research, today announced the launch of DiscoveryAI SAFIR ...
- AI Is Rapidly Transforming Drug Discoveryon February 29, 2024 at 6:01 am
The biopharmaceutical industry stands on the cusp of a revolution, with artificial intelligence emerging as a transformative force in drug development.
- Microsoft partners with Boston biotech to build 'drug discovery on steroids'on February 28, 2024 at 3:59 pm
A Boston biotech is teaming up with tech giant Microsoft to bring AI drug discovery services to pharmaceutical, biotechnology, government, academic, and research institutions across the globe. 1910 ...
- AI Revolutionizing Drug Discovery: Google DeepMind CEO Predicts Drug Design in Clinics within Two Yearson February 26, 2024 at 11:51 pm
In a groundbreaking revelation at the Mobile World Congress in Barcelona, Demis Hassabis, the CEO of Google DeepMind, foresees artificial intelligence (AI) taking the lead in designing drugs directly ...
- Drug Discovery & Development Virtual Event Series 2024on February 21, 2024 at 12:59 pm
Experience the forefront of pharmaceutical innovation as Labroots and the Drug Discovery and Development planning committee host the 7th Annual Event in the Drug Discovery & Development Virtual Event ...
via Bing News